Quo vadis precision oncology?
作者信息
Heinrich Kathrin, Westphalen C Benedikt
机构信息
Comprehensive Cancer Center Munich & Department of Medicine III, University Hospital Munich, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
German Cancer Consortium (DKTK Partner Site Munich), Heidelberg, Germany.
出版信息
J Cancer Res Clin Oncol. 2023 Jan;149(1):3-4. doi: 10.1007/s00432-022-04478-0. Epub 2023 Jan 13.
Abstract
摘要
相似文献
1
Quo vadis precision oncology?
J Cancer Res Clin Oncol. 2023 Jan;149(1):3-4. doi: 10.1007/s00432-022-04478-0. Epub 2023 Jan 13.
2
[Precision medicine in oncology: Challenges, stakes and new paradigms].
Bull Cancer. 2019 Feb;106(2):97-104. doi: 10.1016/j.bulcan.2019.01.007. Epub 2019 Feb 1.
3
Precision oncology: East meets West.
Int J Cancer. 2018 May 1;142(9):1734-1737. doi: 10.1002/ijc.31218. Epub 2018 Jan 4.
4
Understanding the Precision in "Precision Medicine".
Oncologist. 2016 Sep;21(9):1029-30. doi: 10.1634/theoncologist.2016-0278. Epub 2016 Aug 26.
5
Making the right calls in precision oncology.
Nat Biotechnol. 2018 Aug 6;36(8):692-696. doi: 10.1038/nbt.4214.
6
Impact of Precision Medicine in Oncology.
Cancer J. 2023;29(1):1-2. doi: 10.1097/PPO.0000000000000642.
7
Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO).
Ann Oncol. 2014 Sep;25(9):1673-1678. doi: 10.1093/annonc/mdu217. Epub 2014 Jun 20.
8
CRISPR-Cas13a system: a novel approach to precision oncology.
Cancer Biol Med. 2020 Feb 15;17(1):6-8. doi: 10.20892/j.issn.2095-3941.2019.0325.
9
Expanding the Reach of Personalized Medicine in Cancer Care: Current Progress and Future Directions of .
JCO Precis Oncol. 2024 May;8:e2400068. doi: 10.1200/PO.24.00068.
10
Theranostics could be big business in precision oncology.
Nat Med. 2022 Apr;28(4):606-608. doi: 10.1038/s41591-022-01759-6.
本文引用的文献
1
Delivering precision oncology to patients with cancer.
Nat Med. 2022 Apr;28(4):658-665. doi: 10.1038/s41591-022-01717-2. Epub 2022 Apr 19.
2
Lung cancer.
Lancet. 2021 Aug 7;398(10299):535-554. doi: 10.1016/S0140-6736(21)00312-3. Epub 2021 Jul 21.
3
Molecular screening to select therapy for advanced cancer?
Ann Oncol. 2019 May 1;30(5):661-663. doi: 10.1093/annonc/mdz088.
4
Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.
Ann Oncol. 2019 May 1;30(5):757-765. doi: 10.1093/annonc/mdz080.
5
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.
Cancer Discov. 2017 Jun;7(6):586-595. doi: 10.1158/2159-8290.CD-16-1396. Epub 2017 Apr 1.
6
Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.
Br J Cancer. 2014 Jul 8;111(1):17-24. doi: 10.1038/bjc.2014.211. Epub 2014 Apr 24.
7
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
N Engl J Med. 2001 Apr 5;344(14):1038-42. doi: 10.1056/NEJM200104053441402.
8
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
N Engl J Med. 2001 Apr 5;344(14):1031-7. doi: 10.1056/NEJM200104053441401.
Zotero 插件